PSMD8 promotes breast cancer progression and attenuates paclitaxel sensitivity by stabilizing KIF10
Chenyuan Li, Xinyue Nie, Shichong Liao, Feng Yao · 2026
Read PSMD8 promotes breast cancer progression and attenuates paclitaxel sensitivity by stabilizing KIF10 by Chenyuan Li, Xinyue Nie, Shichong Liao, Feng Yao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13563711.txt.
Description
Chenyuan Li and three colleagues chase a protein-shredder part that helps breast cancer spread and blunts a main chemotherapy drug. The part, PSMD8, belongs to the proteasome, the cell's waste-disposal machine. Their 2026 study found PSMD8 overproduced in breast tumours compared with nearby tissue, marking patients with poorer outlooks. Turning the gene down in cancer cells slowed their growth and their shape-shifting spread programme, in dishes and in animals, and it made the drug paclitaxel bite harder. Turning it up did the reverse.
The mechanism runs through a partner protein, KIF10, which PSMD8 shields from destruction. Silencing KIF10 erased PSMD8's tumour-promoting effects, including the drug resistance. The pair's signal fed into the ERK growth pathway, and blocking ERK partly undid the harm. The authors nominate PSMD8 as a target whose removal might both slow breast cancer and restore the power of an existing drug.
Catalog record
| CREATOR | Chenyuan Li, Xinyue Nie, Shichong Liao, Feng Yao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29274 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |